Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Short-term Investments (2021 - 2022)

Bioventus (BVS) has disclosed Short-term Investments for 2 consecutive years, with $23000.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Short-term Investments fell 99.56% year-over-year to $23000.0, compared with a TTM value of $23000.0 through Dec 2022, down 99.56%, and an annual FY2022 reading of $23000.0, down 99.56% over the prior year.
  • Short-term Investments was $23000.0 for Q4 2022 at Bioventus, roughly flat from $23000.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $5.3 million in Q4 2021 and bottomed at $23000.0 in Q4 2022.